Today, STENOCARE has signed a significant contract to establish a large scale, state-of-the-art medical cannabis cultivation facility in Denmark. At the same time, STENOCARE has secured 15mDKK in debt financing which in combination with cash at hand will finance the contract.
Raising the bar:
For more than a year, STENOCARE has been pursuing innovative ways to combine the benefits of scale from green-house cultivation of medical cannabis with the advantages of highly controlled production. In pursuit of this, STENOCARE has selected a global leader in its field, Havecon Horticultural Projects (Netherlands) to co-develop a unique technology/facility that meets extreme demands for control of light, climate and 100% pesticide free in-door cultivation, at scale. This includes 24/7 environmental control through application of “pharma-standard” technology involving air filtration, active climate control with positive pressurized rooms, water treatment and continuous monitoring of all relevant quality parameters and processes.
Thomas Schnegelsberg, CEO of STENOCARE, comments:
“Our Production Director, Søren Kjær, has been working intensively with the specialists at our partner, Havecon Horticultural Projects to arrive at today’s important announcement that we will establish a highly innovative and industry leading cultivation facility. This will play an important role in establishing STENOCARE as a leader in premium medical cannabis”.